Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

This trial is testing a new approach that combines a special radiation-enhancing nanoparticle (NBTXR3) injected directly into tumors, together with high-dose radiation and immunotherapy (a checkpoint inhibitor drug), to treat advanced cancer in the lungs, liver, or soft tissues. **You may be eligible if...** - You are 18 or older with metastatic cancer in the lungs, liver, or soft tissue that cannot be cured - You have at least 2 measurable tumors - Your tumors are accessible for direct injection - You are in reasonably good health (ECOG status 0–2) - You have adequate blood counts, kidney, and liver function - You have not had prior radiation to the target lesion **You may NOT be eligible if...** - You have cancer spread to the brain that is symptomatic - You have active autoimmune disease requiring systemic treatment - You have a history of severe immune-related side effects from prior immunotherapy - You have HIV, active hepatitis B or C - You had a prior organ or stem cell transplant - You are pregnant or breastfeeding - You had another cancer treatment within 2 weeks of planned injection Talk to your doctor to see if this trial is right for you.